63 results about "Protein S" patented technology

The invention provides vectors containing a multiple cloning site comprising a PrS tag or a PrS2 tag from Myxococcus xanthus. Methods are provided for enhancing solubility of a target protein using Protein S tagged target fusion proteins.

The invention relates generally to a new functional protein S assay and kit that is based on the ability of endogenous protein S to prolong clotting time. In the assay procedure, a test plasma sample is diluted with protein S deficient plasma, followed by the addition of purified or recombinant tissue factor (pTF or rTF), purified natural or synthetic phospholipid (pPL or sPL) and activated protein C (APC) or protein C activator (PCA). The clotting time is then measured and compared to a standard curve or a normal control.

Methods are disclosed for determining, in a sample derived from a human, the functional activity of a component of the human blood coagulation system, which activity can be correlated to conversion of a substrate specific for activated Protein C (APC), by measuring in an assay medium containing the sample and a substrate for APC, the conversion of the substrate by APC and correlating the conversion to the functional activity of the component. When the component is anticoagulant Factor V, at least one of exogenous APC, Protein S or an inhibitor of Protein S activity is added to the medium. When the component is Protein C, APC, or Protein S, exogenous anticoagulant Factor V or an inhibitor of anticoagulant activity of Factor V is added to the medium. Methods are also disclosed for diagnosing a blood coagulation / anticoagulation disorder or for determining a predisposition thereto in a human by determining anticoagulant Factor V activity in an assay medium containing a sample derived from the human.

The present invention relates to pro-coagulant human Protein S inhibitors, such as antibodies or antigen-binding fragments thereof that can be administered subcutaneously as prophylactic treatment for haemophilia patients regardless of inhibitor status and without interfering with non-coagulant functions of Protein S.

A pharmaceutical agent for treating a disease such as inflammatory diseases, blood coagulation diseases associated with deficiency of Protein S has been required. The present invention provides a Protein S composition comprising recombinant Protein S molecules having complex type N-glycoside-linked sugar chains, wherein the Protein S has a higher binding activity to a receptor for advanced glycation end products (hereinafter referred to as “RAGE”) than native Protein S present in healthy human blood, and also has a higher ratio of sugar chains in which fucose is not bound to the complex type N-glycoside-linked sugar chains bound to Protein S than native Protein S present in healthy human blood.

The invention provides a fusion protein for a novel coronavirus variant strain Delta, a nasal spray vaccine as well as a preparation method and application thereof, and belongs to the technical field of virus vaccines. The fusion protein for the novel coronavirus variant strain Delta is formed by fusing spike protein S, transmembrane protein M and nucleocapsid protein N; and coding genes of the protein S, the protein M and the protein N are sequentially shown as SEQ ID NO: 1-3. The nasal spray vaccine prepared by mixing the fusion protein and an adjuvant has good immunogenicity, safety and biological activity, and can induce an organism to generate an effective antibody, so that the growth of the novel coronavirus variant strain Delta is inhibited, and the Delta infection can be effectively prevented; by adopting the form of the nasal spray vaccine, injection is not needed, the operation is simple and convenient, and adverse reactions after use of an injection vaccine are avoided; and the preparation method of the vaccine is simple, and the vaccine is easy to purify and high in safety, and can be quickly applied to clinical tests.

In one aspect, described herein is a method for monitoring cognitive decline in a subject, the method comprising (i) determining a level of one or more Dickkopf (Dkk) proteins in a blood sample from the subject; and (ii) comparing the level of the Dkk protein(s) to a reference value; wherein an increased level of the Dkk protein(s) in the sample compared to the reference value is indicative of increased cognitive decline in the subject.

The invention relates to the field of biological medicines and discloses application of protein S (Pros1) as a biological marker in preparation of a reagent for diagnosis of asthma and evaluation of the prognosis effect. The inventors find that the RNA level of Pros1 in peripheral blood of patients suffering from asthma is obviously higher than that of healthy people; further, the ELISA detectionis further performed on Pros1 in peripheral blood of patients suffering from mild and severe asthma and healthy people and finds that the protein level of Pros1 in peripheral blood of patients suffering from severe asthma is obviously higher than that of healthy people; and furthermore, for patients suffering from asthma, the protein level of Pros1 in peripheral blood of patients in the acute stage is higher than that of patients in the remission stage, so that the protein S can serve as the biological marker for diagnosis of asthma and evaluation of the prognosis effect.